Tranexamic Acid Ameliorates Skin Hyperpigmentation by Downregulating Endothelin-1 Expression in Dermal Microvascular Endothelial Cells
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Although reports suggest that tranexamic acid (TXA) has clinical benefits for melasma patients by oral, intralesional and topical treatment, the optimal route of TXA therapy and the underlying mechanism involved remain poorly defined. Objective: To compare the skin lightening effect between oral TXA and topical TXA and to dissect the molecular mechanisms using ultraviolet B (UVB)-induced hyperpigmentation mouse model, ex vivo cultured human skin explant, and cultured melanocytes (MCs) and endothelial cells. Methods: Melanin content and cluster of differentiation 31 (CD31)-positive cell numbers were measured in tail skins from UVB-irradiated mice treated by intragastral or topical TXA using immunofluorescent and Fontana-Masson staining. The conditioned medium (CM) was har vested from human umbilical vein endothelial cells treated with or without 3 mM TXA and was used to treat MCs for 48 hours. mRNA and protein levels of tyrosinase and microphthalmia-associated transcription factor were measured using quantitative real-time reverse transcription polymerase chain reaction and western blotting assays. HMB45- and CD31-positive cell numbers as well as melanin content were also examined in ex vivo cultured human skin explants. Results: The hyperpigmented phenotype were significantly mitigated in UVB-irradiated tail skin plus intragastral TXA-treated mice compared with mice treated with UVB only or with UVB plus topical TXA. CD31-positive cell numbers correlated with the anti-melanogenic activity of TXA ther- apy. The data from cultured cells and skin tissues showed that suppression of endothelin-1 (ET-1) in vascular endothelial cells by TXA reduced melanogenesis and MC proliferation. Conclusion: Oral TXA outperforms topical TXA treatment in skin lightening, which contributes to suppression of ET-1 in dermal microvascular endothelial cells by TXA.
Abstract
Background: Although reports suggest that tranexamic acid (TXA) has clinical benefits for melasma patients by oral, intralesional and topical treatment, the optimal route of TXA therapy and the underlying mechanism involved remain poorly defined. Objective: To compare the skin lightening effect between oral TXA and topical TXA and to dissect the molecular mechanisms using ultraviolet B (UVB)-induced hyperpigmentation mouse model, ex vivo cultured human skin explant, and cultured melanocytes (MCs) and endothelial cells. Methods: Melanin content and cluster of differentiation 31 (CD31)-positive cell numbers were measured in tail skins from UVB-irradiated mice treated by intragastral or topical TXA using immunofluorescent and Fontana-Masson staining. The conditioned medium (CM) was har vested from human umbilical vein endothelial cells treated with or without 3 mM TXA and was used to treat MCs for 48 hours. mRNA and protein levels of tyrosinase and microphthalmia-associated transcription factor were measured using quantitative real-time reverse transcription polymerase chain reaction and western blotting assays. HMB45- and CD31-positive cell numbers as well as melanin content were also examined in ex vivo cultured human skin explants. Results: The hyperpigmented phenotype were significantly mitigated in UVB-irradiated tail skin plus intragastral TXA-treated mice compared with mice treated with UVB only or with UVB plus topical TXA. CD31-positive cell numbers correlated with the anti-melanogenic activity of TXA ther- apy. The data from cultured cells and skin tissues showed that suppression of endothelin-1 (ET-1) in vascular endothelial cells by TXA reduced melanogenesis and MC proliferation. Conclusion: Oral TXA outperforms topical TXA treatment in skin lightening, which contributes to suppression of ET-1 in dermal microvascular endothelial cells by TXA.
참고문헌 (30)
- Rajanala S, "Melasma pathogenesis : a review of the latest research, pathological findings, and investigational therapies", Dermatol Online J, 25, pp.13030~ (2019)
- Wang RF, "Disorders of hyperpigmentation. Part I. Pathogenesis and clinical features of common pigmentary disorders", J Am Acad Dermatol, 88, pp.271~288 (2023)
- Mahajan VK, "Medical therapies for melasma", J Cosmet Dermatol, 21, pp.3707~3728 (2022)
- Ogbechie-Godec OA, "Melasma : an up-to-date comprehensive review", Dermatol Ther(Heidelb), 7, pp.305~318 (2017)
- Espósito ACC, "Exploring pathways for sustained melanogenesis in facial melasma : an immunofluorescence study", Int J Cosmet Sci, 40, pp.420~424 (2018)
- Neagu N, "Melasma treatment : a systematic review", J Dermatolog Treat, 33, pp.1816~1837 (2022)
- Espósito ACC, "Exploratory study of epidermis, basement membrane zone, upper dermis alterations and Wnt pathway activation in melasma compared to adjacent and retroauricular skin", Ann Dermatol, 32, pp.101~108 (2020)
- Phansuk K, "Dermal pathology in melasma : an update review", Clin Cosmet Investig Dermatol, 15, pp.11~19 (2022)
- Hu ZM, "Effects of hydroquinone and its glucoside derivatives on melanogenesis and antioxidation : biosafety as skin whitening agents", J Dermatol Sci, 55, pp.179~184 (2009)
- McKesey J, "Melasma treatment : an evidence-based review", Am J Clin Dermatol, 21, pp.173~225 (2020)
- Gao TW, "Consensus on the diagnosis and treatment of melasma in China(2021 version)", Int J Dermatol Venerol, 4, pp.134~139 (2021)
- Sheu SL, "Treatment of melasma using tranexamic acid : what’s known and what’s next", Cutis, 101, pp.E7~E8 (2018)
- Godse K, "Oral tranexamic acid for the treatment of melasma : evidence and experience-based consensus statement from Indian experts", Indian J Dermatol, 68, pp.178~185 (2023)
- Konisky H, "Tranexamic acid in melasma : a focused review on drug administration routes", J Cosmet Dermatol, 22, pp.1197~1206 (2023)
- Tan AWM, "Oral tranexamic acid lightens refractory melasma", Australas J Dermatol, 58, pp.e105~e108 (2017)
- Mackenzie MA, "Activation of the receptor tyrosine kinase Kit is required for the proliferation of melanoblasts in the mouse embryo", Dev Biol, 192, pp.99~107 (1997)
- Hiramoto K, "Tranexamic acid suppresses ultraviolet B eye irradiation-induced melanocyte activation by decreasing the levels of prohormone convertase 2 and alpha-melanocyte-stimulating hormone", Photodermatol Photoimmunol Photomed, 30, pp.302~307 (2014)
- Neil JE, "Human skin explant model for the investigation of topical therapeutics", Sci Rep, 10, pp.21192~ (2020)
- Hu SH, "sPmel17 secreted by ultraviolet B-exposed melanocytes alters the intercellular adhesion of keratinocytes", Oxid Med Cell Longev, 2022, pp.1856830~ (2022)
- Yao YZ, "Uncoupling melanogenesis from proliferation in epidermal melanocytes responding to stimulation with psoriasis-related proinflammatory cytokines", J Dermatol Sci, 108, pp.98~108 (2022)
- Kim H, "CD31+ cells represent highly angiogenic and vasculogenic cells in bone marrow : novel role of nonendothelial CD31+ cells in neovascularization and their therapeutic effects on ischemic vascular disease", Circ Res, 107, pp.602~614 (2010)
- Regazzetti C, "Endothelial cells promote pigmentation through endothelin receptor B activation", J Invest Dermatol, 135, pp.3096~3104 (2015)
- Rubin LJ, "Bosentan : a dual endothelin receptor antagonist", Expert Opin Investig Drugs, 11, pp.991~1002 (2002)
- Geddes ER, "Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595-nm pulsed dye laser combined with the 1927-nm fractional low-powered diode laser", Lasers Surg Med, 49, pp.20~26 (2017)
- Cassiano DP, "Histological changes in facial melasma after treatment with triple combination cream with or without oral tranexamic acid and", or microneedling : a randomised clinical trial, 2022, pp.88, 761~770
- Lee HC, "Oral tranexamic acid(TA)in the treatment of melasma : a retrospective analysis", J Am Acad Dermatol, 75, pp.385~392 (2016)
- Konisky H, "Tranexamic acid in melasma : a focused review on drug administration routes", J Cosmet Dermatol, 22, pp.1197~1206 (2023)
- Mamdouh Kamal Dawaud S, "Efficacy and safety of topical tranexamic acid alone or in combination with either fractional carbon dioxide laser or microneedling for the treatment of melasma", Dermatol Pract Concept, 13, pp.e2023195~ (2023)
- de Freitas ACP, "Perspectives of topical formulations for melasma", Int J Dermatol, 62, pp.260~268 (2023)
- Sanchez MM, "Development of a vascularized human skin equivalent with hypodermis for photoaging studies", Biomolecules, 12, pp.1828~ (2022)